1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Exenatide 1.2.3 Liraglutide 1.2.4 Others 1.3 Market by Application 1.3.1 Global Peptide Based Metabolic Disorders Therapeutics Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Hospital Pharmacies 1.3.3 Retail Pharmacies 1.3.4 Online Pharmacies 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Peptide Based Metabolic Disorders Therapeutics Market Perspective (2017-2028) 2.2 Peptide Based Metabolic Disorders Therapeutics Growth Trends by Region 2.2.1 Peptide Based Metabolic Disorders Therapeutics Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Region (2017-2022) 2.2.3 Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Region (2023-2028) 2.3 Peptide Based Metabolic Disorders Therapeutics Market Dynamics 2.3.1 Peptide Based Metabolic Disorders Therapeutics Industry Trends 2.3.2 Peptide Based Metabolic Disorders Therapeutics Market Drivers 2.3.3 Peptide Based Metabolic Disorders Therapeutics Market Challenges 2.3.4 Peptide Based Metabolic Disorders Therapeutics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Peptide Based Metabolic Disorders Therapeutics Players by Revenue 3.1.1 Global Top Peptide Based Metabolic Disorders Therapeutics Players by Revenue (2017-2022) 3.1.2 Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Players (2017-2022) 3.2 Global Peptide Based Metabolic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Peptide Based Metabolic Disorders Therapeutics Revenue 3.4 Global Peptide Based Metabolic Disorders Therapeutics Market Concentration Ratio 3.4.1 Global Peptide Based Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Peptide Based Metabolic Disorders Therapeutics Revenue in 2021 3.5 Peptide Based Metabolic Disorders Therapeutics Key Players Head office and Area Served 3.6 Key Players Peptide Based Metabolic Disorders Therapeutics Product Solution and Service 3.7 Date of Enter into Peptide Based Metabolic Disorders Therapeutics Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Peptide Based Metabolic Disorders Therapeutics Breakdown Data by Type 4.1 Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Type (2017-2022) 4.2 Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Type (2023-2028) 5 Peptide Based Metabolic Disorders Therapeutics Breakdown Data by Application 5.1 Global Peptide Based Metabolic Disorders Therapeutics Historic Market Size by Application (2017-2022) 5.2 Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Peptide Based Metabolic Disorders Therapeutics Market Size (2017-2028) 6.2 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) 6.3 North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Peptide Based Metabolic Disorders Therapeutics Market Size (2017-2028) 7.2 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) 7.3 Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size (2017-2028) 8.2 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) 8.3 Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size (2017-2028) 9.2 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) 9.3 Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size (2017-2028) 10.2 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) 10.3 Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 AstraZeneca 11.1.1 AstraZeneca Company Detail 11.1.2 AstraZeneca Business Overview 11.1.3 AstraZeneca Peptide Based Metabolic Disorders Therapeutics Introduction 11.1.4 AstraZeneca Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) 11.1.5 AstraZeneca Recent Development 11.2 Ingro Finanz (Bachem) 11.2.1 Ingro Finanz (Bachem) Company Detail 11.2.2 Ingro Finanz (Bachem) Business Overview 11.2.3 Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Introduction 11.2.4 Ingro Finanz (Bachem) Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) 11.2.5 Ingro Finanz (Bachem) Recent Development 11.3 Eli Lilly 11.3.1 Eli Lilly Company Detail 11.3.2 Eli Lilly Business Overview 11.3.3 Eli Lilly Peptide Based Metabolic Disorders Therapeutics Introduction 11.3.4 Eli Lilly Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) 11.3.5 Eli Lilly Recent Development 11.4 Ipsen 11.4.1 Ipsen Company Detail 11.4.2 Ipsen Business Overview 11.4.3 Ipsen Peptide Based Metabolic Disorders Therapeutics Introduction 11.4.4 Ipsen Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) 11.4.5 Ipsen Recent Development 11.5 Merck 11.5.1 Merck Company Detail 11.5.2 Merck Business Overview 11.5.3 Merck Peptide Based Metabolic Disorders Therapeutics Introduction 11.5.4 Merck Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) 11.5.5 Merck Recent Development 11.6 Novo Nordisk 11.6.1 Novo Nordisk Company Detail 11.6.2 Novo Nordisk Business Overview 11.6.3 Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Introduction 11.6.4 Novo Nordisk Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) 11.6.5 Novo Nordisk Recent Development 11.7 PolyPeptide Group 11.7.1 PolyPeptide Group Company Detail 11.7.2 PolyPeptide Group Business Overview 11.7.3 PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Introduction 11.7.4 PolyPeptide Group Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) 11.7.5 PolyPeptide Group Recent Development 11.8 Teva Pharmaceutical 11.8.1 Teva Pharmaceutical Company Detail 11.8.2 Teva Pharmaceutical Business Overview 11.8.3 Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Introduction 11.8.4 Teva Pharmaceutical Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) 11.8.5 Teva Pharmaceutical Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Exenatide Table 3. Key Players of Liraglutide Table 4. Key Players of Others Table 5. Global Peptide Based Metabolic Disorders Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 6. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2017-2022) & (US$ Million) Table 8. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Region (2017-2022) Table 9. Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 10. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Region (2023-2028) Table 11. Peptide Based Metabolic Disorders Therapeutics Market Trends Table 12. Peptide Based Metabolic Disorders Therapeutics Market Drivers Table 13. Peptide Based Metabolic Disorders Therapeutics Market Challenges Table 14. Peptide Based Metabolic Disorders Therapeutics Market Restraints Table 15. Global Peptide Based Metabolic Disorders Therapeutics Revenue by Players (2017-2022) & (US$ Million) Table 16. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Players (2017-2022) Table 17. Global Top Peptide Based Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Based Metabolic Disorders Therapeutics as of 2021) Table 18. Ranking of Global Top Peptide Based Metabolic Disorders Therapeutics Companies by Revenue (US$ Million) in 2021 Table 19. Global 5 Largest Players Market Share by Peptide Based Metabolic Disorders Therapeutics Revenue (CR5 and HHI) & (2017-2022) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Peptide Based Metabolic Disorders Therapeutics Product Solution and Service Table 22. Date of Enter into Peptide Based Metabolic Disorders Therapeutics Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Type (2017-2022) & (US$ Million) Table 25. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Type (2017-2022) Table 26. Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 27. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Type (2023-2028) Table 28. Global Peptide Based Metabolic Disorders Therapeutics Market Size by Application (2017-2022) & (US$ Million) Table 29. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Application (2017-2022) Table 30. Global Peptide Based Metabolic Disorders Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 31. Global Peptide Based Metabolic Disorders Therapeutics Revenue Market Share by Application (2023-2028) Table 32. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 33. North America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 34. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 35. Europe Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 36. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2017-2022) & (US$ Million) Table 37. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size by Region (2023-2028) & (US$ Million) Table 38. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 39. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 40. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 41. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 42. AstraZeneca Company Detail Table 43. AstraZeneca Business Overview Table 44. AstraZeneca Peptide Based Metabolic Disorders Therapeutics Product Table 45. AstraZeneca Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million) Table 46. AstraZeneca Recent Development Table 47. Ingro Finanz (Bachem) Company Detail Table 48. Ingro Finanz (Bachem) Business Overview Table 49. Ingro Finanz (Bachem) Peptide Based Metabolic Disorders Therapeutics Product Table 50. Ingro Finanz (Bachem) Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million) Table 51. Ingro Finanz (Bachem) Recent Development Table 52. Eli Lilly Company Detail Table 53. Eli Lilly Business Overview Table 54. Eli Lilly Peptide Based Metabolic Disorders Therapeutics Product Table 55. Eli Lilly Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million) Table 56. Eli Lilly Recent Development Table 57. Ipsen Company Detail Table 58. Ipsen Business Overview Table 59. Ipsen Peptide Based Metabolic Disorders Therapeutics Product Table 60. Ipsen Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million) Table 61. Ipsen Recent Development Table 62. Merck Company Detail Table 63. Merck Business Overview Table 64. Merck Peptide Based Metabolic Disorders Therapeutics Product Table 65. Merck Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million) Table 66. Merck Recent Development Table 67. Novo Nordisk Company Detail Table 68. Novo Nordisk Business Overview Table 69. Novo Nordisk Peptide Based Metabolic Disorders Therapeutics Product Table 70. Novo Nordisk Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million) Table 71. Novo Nordisk Recent Development Table 72. PolyPeptide Group Company Detail Table 73. PolyPeptide Group Business Overview Table 74. PolyPeptide Group Peptide Based Metabolic Disorders Therapeutics Product Table 75. PolyPeptide Group Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million) Table 76. PolyPeptide Group Recent Development Table 77. Teva Pharmaceutical Company Detail Table 78. Teva Pharmaceutical Business Overview Table 79. Teva Pharmaceutical Peptide Based Metabolic Disorders Therapeutics Product Table 80. Teva Pharmaceutical Revenue in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million) Table 81. Teva Pharmaceutical Recent Development Table 82. Research Programs/Design for This Report Table 83. Key Data Information from Secondary Sources Table 84. Key Data Information from Primary Sources List of Figures Figure 1. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Type: 2021 VS 2028 Figure 2. Exenatide Features Figure 3. Liraglutide Features Figure 4. Others Features Figure 5. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Application in 2021 & 2028 Figure 6. Hospital Pharmacies Case Studies Figure 7. Retail Pharmacies Case Studies Figure 8. Online Pharmacies Case Studies Figure 9. Peptide Based Metabolic Disorders Therapeutics Report Years Considered Figure 10. Global Peptide Based Metabolic Disorders Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 11. Global Peptide Based Metabolic Disorders Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 12. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Region: 2021 VS 2028 Figure 13. Global Peptide Based Metabolic Disorders Therapeutics Market Share by Players in 2021 Figure 14. Global Top Peptide Based Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Based Metabolic Disorders Therapeutics as of 2021) Figure 15. The Top 10 and 5 Players Market Share by Peptide Based Metabolic Disorders Therapeutics Revenue in 2021 Figure 16. North America Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 17. North America Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2017-2028) Figure 18. United States Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 19. Canada Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 20. Europe Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Europe Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2017-2028) Figure 22. Germany Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. France Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. U.K. Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. Italy Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. Russia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Nordic Countries Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Asia-Pacific Peptide Based Metabolic Disorders Therapeutics Market Share by Region (2017-2028) Figure 30. China Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Japan Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. South Korea Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Southeast Asia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. India Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. Australia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Latin America Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2017-2028) Figure 38. Mexico Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Brazil Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Middle East & Africa Peptide Based Metabolic Disorders Therapeutics Market Share by Country (2017-2028) Figure 42. Turkey Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Saudi Arabia Peptide Based Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. AstraZeneca Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) Figure 45. Ingro Finanz (Bachem) Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) Figure 46. Eli Lilly Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) Figure 47. Ipsen Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) Figure 48. Merck Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) Figure 49. Novo Nordisk Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) Figure 50. PolyPeptide Group Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) Figure 51. Teva Pharmaceutical Revenue Growth Rate in Peptide Based Metabolic Disorders Therapeutics Business (2017-2022) Figure 52. Bottom-up and Top-down Approaches for This Report Figure 53. Data Triangulation Figure 54. Key Executives Interviewed

AstraZeneca Ingro Finanz (Bachem) Eli Lilly Ipsen Merck Novo Nordisk PolyPeptide Group Teva Pharmaceutical